Cladribine with Granulocyte Colony‐Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study

LESSONS LEARNED: Studies targeting cladribine in combination with granulocyte colony‐stimulating factor, low‐dose cytarabine, and aclarubicin (C‐CAG) regimen in relapsed and refractory acute myeloid leukemia (R/R AML) are limited. The complete remission rate after two cycles of C‐CAG regimen was 67....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hua, Wang, Liang, Li, Chun, Wuxiao, Zhijun, Shao, Ruonan, Wang, Huizhong, Lu, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648354/
https://www.ncbi.nlm.nih.gov/pubmed/32845551
http://dx.doi.org/10.1634/theoncologist.2020-0818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648354/
https://www.ncbi.nlm.nih.gov/pubmed/32845551
http://dx.doi.org/10.1634/theoncologist.2020-0818

Ejemplares similares